Imagen de Portada

Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2

Guardado en:
Publicado en:bioRxiv (Mar 9, 2022), p. n/a
Autor principal: Dangi, Tanushree
Otros Autores: Sanchez, Sarah, Park, Mincheol, Class, Jacob, Richner, Michelle C, Richner, Justin M, Penaloza-Macmaster, Pablo
Publicado:
Cold Spring Harbor Laboratory Press
Materias:
Coronaviruses
Spike protein
Severe acute respiratory syndrome coronavirus 2
COVID-19 vaccines
COVID-19
Immunotherapy
Vaccines
Monoclonal antibodies
Proteins
Nucleocapsids
Acceso en línea:Citation/Abstract
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:The spike protein of SARS-CoV-2 is a critical antigen present in all approved SARS-CoV-2 vaccines. This surface viral protein is also the target for all monoclonal antibody therapies, but it is unclear whether antibodies targeting other viral proteins can also improve protection against COVID-19. Here, we interrogate whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine, and then transferred sera from these mice into naive mice. On the next day, the recipient mice were challenged intranasally with SARS-CoV-2 to evaluate whether nucleocapsid-specific humoral responses affect viral control. Interestingly, mice that received nucleocapsid-specific sera exhibited enhanced control of a SARS-CoV-2 infection. These findings provide the first demonstration that humoral responses specific to an internal coronavirus protein can help clear infection, warranting the inclusion of other viral antigens in next-generation SARS-CoV-2 vaccines and providing a rationale for the clinical evaluation of nucleocapsid-specific monoclonals to treat COVID-19. Competing Interest Statement The authors have declared no competing interest.
ISSN:2692-8205
DOI:10.1101/2022.03.09.483635
Fuente:Biological Science Database